Organofluorides

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease

Retrieved on: 
Tuesday, June 29, 2021
Neurological disorders, Organic compounds, Parkinson's disease, Branches of biology, Dipraglurant, Imidazopyridines, Organofluorides, Levodopa-induced dyskinesia, Catecholamines, Dyskinesia, L-DOPA

We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.

Key Points: 
  • We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.
  • In a Phase 2a study dipraglurant met its primary endpoint by being generally well tolerated and showing no clinically significant safety issues.
  • However, the development of dyskinesia which may be associated with long-term use of levodopa can become as disabling as the symptoms of Parkinson's disease.
  • Addexs lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) is in a pivotal registration clinical trial for Parkinsons disease levodopa induced dyskinesia (PD-LID).

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Retrieved on: 
Thursday, June 24, 2021
Clinical trials, ClinicalTrials.gov, Organofluorides

This is a similar patient population and the same endpoint as was tested in Corbus previously completed Phase 2 study (ClinicalTrials.gov Identifier: NCT02466243).

Key Points: 
  • This is a similar patient population and the same endpoint as was tested in Corbus previously completed Phase 2 study (ClinicalTrials.gov Identifier: NCT02466243).
  • Efficacy results for the lenabasum 5 mg twice daily group were generally similar to those for the control group.
  • There were fewer AEs of dermatomyositis worsening in the lenabasum 20 mg twice daily group than the control group (27 versus 44).
  • Nonetheless, we are encouraged by the results when the outcome is matched to the subtype of dermatomyositis in the study.

A-Gas Expands Services in Minneapolis Market

Retrieved on: 
Wednesday, June 23, 2021
Oil, Gas, Manufacturing, Energy, Environment, Chemicals, Plastics, Countries, Foreign relations, Government, Heating, ventilation, and air conditioning, Organofluorides, Industrial gases, Refrigerants, Ozone depletion, Chlorofluorocarbon, Hydrofluorocarbon, Organofluorine chemistry, Fluorine

Following our entry into the Minnesota marketplace in 2018, weve experienced rapid growth, comments A-Gass Vice President of Refrigerants, Taylor Ferranti.

Key Points: 
  • Following our entry into the Minnesota marketplace in 2018, weve experienced rapid growth, comments A-Gass Vice President of Refrigerants, Taylor Ferranti.
  • Demand from customers, suppliers, and key industry partners for A-Gass broad suite of environmental solutions, creates an attractive position for expansion in Minnesota.
  • The United States will start the phasedown of hydrofluorocarbons (HFCs) in six months, and A-Gas has a broad portfolio of products and services to ease this transition for our customers and partners.
  • The companys core business offers environmental solutions and lifecycle management services for ozone depleting substances and global warming agents including CFCs, HCFCs, HFCs and Halons in the HVAC/Refrigeration and Fire Suppression Industries.

Global Engineered Fluids Market (2020 to 2028) - Size, Share & Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Engineering, Chemicals, Plastics, Manufacturing, Chemistry, Organic polymers, Physical sciences, Plastics, Fluoropolymers, Thermoplastics, Biomaterials, Organofluorides, Polyvinyl fluoride, Fluorine, Polyvinylidene fluoride, Polytetrafluoroethylene

The "Engineered Fluids (Fluorinated Fluids) Market Size, Share & Analysis, By Polymer [Polytetrafluoroethylene (PTFE), Polyvinyl Fluoride (PVF), Polyvinylidene Fluoride (PVDF), and Others], By Product Type, By Industry Vertical, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Engineered Fluids (Fluorinated Fluids) Market Size, Share & Analysis, By Polymer [Polytetrafluoroethylene (PTFE), Polyvinyl Fluoride (PVF), Polyvinylidene Fluoride (PVDF), and Others], By Product Type, By Industry Vertical, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com's offering.
  • Market Size - USD 1,018.5 Million in 2020, Market Growth - CAGR of 7.7%, Market Trends - Increasing investments and focus of manufacturers on innovations and rising preference for environmentally safe lubricating products.
  • The global engineered fluids (fluorinated fluids) market size is expected to reach USD 1,854.9 Million in 2028, and register a CAGR of 7.7% during the forecast period.
  • Growing demand and preference for lightweight aerospace components and automotive parts, coupled with increasing consumption of engineered fluids for variety of applications in these industries are other major factors boosting growth of the global engineered fluids market to a significant extent.

Flucytosine (CAS 2341-22-2) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Health, General Health, Flucytosine, Nucleobases, Organofluorides, Branches of biology

The "Flucytosine (CAS 2341-22-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Flucytosine (CAS 2341-22-2) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of flucytosine.
  • The fifth chapter deals with flucytosine market trends and forecast, distinguish flucytosine manufacturers and suppliers.
  • The flucytosine global market report key points:

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Retrieved on: 
Thursday, June 10, 2021
Data management, Chemical compounds, 5-HT2A antagonists, Antipsychotics, Ketones, Organofluorides, Piperidines, Roluperidone, NERV, NASDAQ, Schizophrenia, JMP

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time.
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned

Retrieved on: 
Wednesday, June 9, 2021
Protease inhibitor, Antiviral drugs, Draft:Sunshine Biopharma, Carbamates, Organofluorides, HIV protease inhibitors

The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.

Key Points: 
  • The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.
  • Sunshine Biopharmas protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home.
  • We are moving the project forward as fast as possible, albeit within the constraints of science, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

Retrieved on: 
Wednesday, June 2, 2021
Medical specialties, Clinical medicine, Drugs, Rheumatology, Organofluorides, Pyrrolidines, Upadacitinib, Ureas, Rheumatoid arthritis, Adalimumab, Arthritis, Filgotinib

The integrated safety analysis included pooled data from six randomized, controlled RINVOQ rheumatoid arthritis clinical trials.

Key Points: 
  • The integrated safety analysis included pooled data from six randomized, controlled RINVOQ rheumatoid arthritis clinical trials.
  • Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 years From the SELECT-COMPARE Study.
  • Integrated Safety Profile of Upadacitinib With up to 4.5 Years of Exposure in Patients With Rheumatoid Arthritis (RA Integrated Safety Update).
  • Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 weeks from the SELECT-COMPARE Study.

CBMG Holdings Announces Data from Two CAR-T Clinical Studies Selected for Podium Presentations at ASCO Annual Meeting

Retrieved on: 
Tuesday, June 1, 2021
Clinical medicine, Cancer treatments, Drugs, Arabinosides, Fludarabine, Organofluorides, Organophosphates, Purines, Cyclophosphamide, Chimeric antigen receptor T cell, Cancer immunotherapy, Oncology

GMP manufacture of C-CAR066 was in a serum free and fully closed semi-automatic system.

Key Points: 
  • GMP manufacture of C-CAR066 was in a serum free and fully closed semi-automatic system.
  • A 3-day cyclophosphamide plus fludarabine regimen was followed by a single infusion of C-CAR066.
  • C-CAR066 has shown a favorable safety profile and promising efficacy in patients with r/r B-NHL following failure of CD19 CAR-T therapy.
  • The company conducts immuno-oncology and stem cell clinical trials inChinausing products from its integrated GMP laboratory.

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Friday, May 28, 2021
Chemical compounds, 5-HT2A antagonists, Antipsychotics, Ketones, Organofluorides, Piperidines, Roluperidone, NERV, Schizophrenia, Chemistry

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .